SCM
ASMB icon

Soleus Capital Management’s Assembly Biosciences ASMB Stock Holding History

Soleus Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-93,500
Closed -$3.9M – 69
2021
Q3 		$3.9M Hold
93,500
– – 0.61% 40
2021
Q2 		$4.35M Hold
93,500
– – 0.67% 30
2021
Q1 		$5.16M Buy
+93,500
New +$6.2M 0.93% 20

Other funds holding ASMB

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Soleus Capital Management's ASMB Position: Q4 2021 in Review

Soleus Capital Management sold out of Assembly Biosciences (ASMB) in Q4 2021, closing a stake of 93,500 shares — an estimated $3.9M sold.

Soleus Capital Management first reported a position in ASMB in Q1 2021 and held it in 3 quarters. The position peaked at $5.16M in Q1 2021. 62 funds tracked by Wall St. Rank hold ASMB as of Q4 2021.

  • Soleus Capital Management reported no remaining Assembly Biosciences position as of Q4 2021 after selling out during the quarter.
  • Soleus Capital Management sold 93,500 Assembly Biosciences shares in Q4 2021, an estimated $3.9M.
  • Soleus Capital Management first reported a position in Assembly Biosciences in Q1 2021 and held it in 3 quarters.
  • Soleus Capital Management's Assembly Biosciences position peaked at $5.16M in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2021.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.